Peptide oligonucleotide conjugates
First Claim
Patent Images
1. A conjugate comprising:
- (a) a carrier peptide comprising amino acid subunits, the carrier peptide comprising a glycine (G) amino acid subunit at the carboxy terminus of the carrier peptide;
(b) a nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid; and
(c) a covalent attachment between the nucleic acid analog and the carrier peptide, the covalent attachment comprising the carboxy-terminal glycine and an optional linker group;
wherein;
two or more of the amino acid subunits are positively charged amino acids, no more than seven contiguous amino acid subunits are arginine, and the covalent attachment between the nucleic acid analog and the carrier peptide is not 6-aminohexanoic acid or β
-alanine.
2 Assignments
0 Petitions
Accused Products
Abstract
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
-
Citations
81 Claims
-
1. A conjugate comprising:
-
(a) a carrier peptide comprising amino acid subunits, the carrier peptide comprising a glycine (G) amino acid subunit at the carboxy terminus of the carrier peptide; (b) a nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid; and (c) a covalent attachment between the nucleic acid analog and the carrier peptide, the covalent attachment comprising the carboxy-terminal glycine and an optional linker group; wherein; two or more of the amino acid subunits are positively charged amino acids, no more than seven contiguous amino acid subunits are arginine, and the covalent attachment between the nucleic acid analog and the carrier peptide is not 6-aminohexanoic acid or β
-alanine.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)
-
-
33. The conjugate of claim 32, wherein at least one of the morpholino ring structures has the following structure (i):
-
34. The conjugate of claim 32, wherein at least one of the intersubunit linkages is linkage (A).
-
35. The conjugate of claim 32, wherein each of the intersubunit linkages is linkage (A).
-
36. The conjugate of claim 32, wherein each linkage (A) has the same structure at each occurrence.
-
37. The conjugate of claim 32, wherein for at least one occurrence of linkage (A), X is —
- N(CH3)2.
-
38. The conjugate of claim 32, wherein X is —
- N(CH3)2 at each occurrence of linkage (A).
-
39. The conjugate of claim 32, wherein each linkage is linkage (A) and X is —
- N(CH3)2.
-
40. The conjugate of claim 32, wherein for at least one occurrence of linkage (A), X has the following structure:
-
41. The conjugate of claim 32, wherein for at least one occurrence of linkage (B), X has the following structure:
-
42. The conjugate of claim 32, wherein for at least one occurrence of linkage (B), X has the following structure:
-
43. The conjugate of claim 32, wherein W and Y are each O at each occurrence.
-
44. The conjugate of claim 32, wherein at least 5% of the intersubunit linkages are linkage (B).
-
45. The conjugate of claim 32, wherein each linkage (B) has the same structure at each occurrence.
-
46. The conjugate of claim 32, wherein the conjugate has the following structure (XVII):
-
47. The conjugate of claim 46, wherein R18 is the carrier peptide.
-
48. The conjugate of claim 46, wherein R19 is the carrier peptide.
-
49. The conjugate of claim 46, wherein at least one of R18 or R19 is R20.
-
50. The conjugate of claim 46, wherein R19 is —
- C(═
O)OR21.
- C(═
-
51. The conjugate of claim 50, wherein R19 is
-
52. The conjugate of claim 46, wherein L1 comprises phosphorodiamidate and piperazine bonds.
-
53. The conjugate of claim 52, wherein L1 has the following structure (XXIX):
-
54. The conjugate of claim 53, wherein R24 is absent.
-
55. The conjugate of claim 46, wherein R18 is the carrier peptide, L2 is a direct bond, and the carrier peptide forms a bond between the carboxy terminus of the carrier peptide and the 3′
- terminal nitrogen of the nucleic acid analogue.
-
56. A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable vehicle.
-
57. A method of treating a disease in a subject, the method comprising administering a therapeutically effective amount of the conjugate of claim 1 to the subject.
-
58. The method of claim 57, wherein the disease is a viral infection, a neuromuscular disease, a bacterial infection, inflammation or polycystic kidney disease.
-
59. The method of claim 58, wherein the viral infection is influenza.
-
60. The method of claim 58, wherein the neuromuscular disease is Duchenne muscular dystrophy.
-
61. The conjugate of claim 1, wherein the covalent attachment includes the optional linker.
-
62. The conjugate of claim 1, wherein the glycine amino acid subunit is covalently linked to the nucleic acid analogue at the 5′
- end of the nucleic acid analogue.
-
63. The conjugate of claim 1, wherein the glycine amino acid subunit is covalently linked to the nucleic acid analogue at the 3′
- end of the nucleic acid analogue.
-
64. The conjugate of claim 46, wherein the carrier peptide is selected from SEQ ID NOS:
- 60, 69, 70, 89-121, 125, 130-160, 162-257, 276, 277, 281-288, 293-297, 300, 302-412, 419-552, and 554-566.
-
65. The conjugate of claim 46, wherein the carrier peptide is selected from SEQ ID NOS:
- 130, 157-160, 251, 256, 386-388, and 540.
-
66. The conjugate of claim 46, wherein the carrier peptide is SEQ ID NO:
- 159.
-
67. The conjugate of claim 1, wherein the carrier peptide is of a formula selected from:
-
68. The conjugate of claim 67, wherein the carrier peptide is of the formula:
-
69. The conjugate of claim 1, wherein the conjugate is selected from
-
70. The conjugate of claim 69, wherein the carrier peptide is selected from SEQ ID NOS:
- 130, 157-160, 251, 256, 386-388, and 540.
-
71. The conjugate of claim 69, wherein the carrier peptide is SEQ ID NO:
- 159.
-
72. The conjugate of claim 1, wherein the conjugate is selected from:
-
73. The conjugate of claim 72, wherein the carrier peptide is selected from SEQ ID NOS:
- 130, 157-160, 251, 256, 386-388, and 540.
-
74. The conjugate of claim 72, wherein the carrier is SEQ ID NO:
- 159.
-
75. The conjugate of claim 72, wherein each Pi is independently selected from adenine, cytosine, guanine, uracil, thymine, and inosine.
- 76. A compound selected from:
Specification